March 21, 2025VantAI Launches Neo-1VantAI launches Neo-1, the first AI model to rewire molecular interactions by unifying structure prediction and generation for therapeutic design.
May 22, 2024VantAI Expands Scientific Advisory Board with Leaders in Protein Design and Generative AIVantAI, a company focused on generative AI-enabled drug discovery, today announced the appointments of Dr. Ian Churcher and Dr. Bradley Pentelute to its Scientific Advisory Board (SAB).
May 08, 2024VantAI Appoints John Cuozzo as Senior Vice President, Head of Drug DiscoveryVantAI, a leader in generative AI and drug discovery, today announced the appointment of John Cuozzo, PhD as SVP, Head of Drug Discovery. Cuozzo is an experienced scientific leader with a strong track record of building novel discovery platforms and leading successful drug discovery programs.
May 01, 2024VantAI Collaborates With Google Cloud to Harness NVIDIA GPUs for Building Protein Interaction Foundation ModelsVantAI will leverage its proprietary large scale structural data and NVIDIA H100 GPUs on Google Cloud to enable a step-change in accuracy for all-atom protein interaction prediction.
March 21, 2025VantAI Launches Neo-1VantAI launches Neo-1, the first AI model to rewire molecular interactions by unifying structure prediction and generation for therapeutic design.
May 22, 2024VantAI Expands Scientific Advisory Board with Leaders in Protein Design and Generative AIVantAI, a company focused on generative AI-enabled drug discovery, today announced the appointments of Dr. Ian Churcher and Dr. Bradley Pentelute to its Scientific Advisory Board (SAB).
May 08, 2024VantAI Appoints John Cuozzo as Senior Vice President, Head of Drug DiscoveryVantAI, a leader in generative AI and drug discovery, today announced the appointment of John Cuozzo, PhD as SVP, Head of Drug Discovery. Cuozzo is an experienced scientific leader with a strong track record of building novel discovery platforms and leading successful drug discovery programs.
May 01, 2024VantAI Collaborates With Google Cloud to Harness NVIDIA GPUs for Building Protein Interaction Foundation ModelsVantAI will leverage its proprietary large scale structural data and NVIDIA H100 GPUs on Google Cloud to enable a step-change in accuracy for all-atom protein interaction prediction.
February 13, 2024VantAI Enters Collaboration With Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial IntelligenceVantAI, a company focused on generative AI-enabled drug discovery, and Bristol Myers Squibb, a leading pharmaceutical company, have entered into a strategic collaboration to discover new molecular glues for therapeutic targets of interest.
February 07, 2024VantAI Appoints Jae Won Kim as Chief Operating Officer and Chief Financial OfficerVantAI, a leader in generative AI and drug discovery, announced the appointment of Jae Won Kim as Chief Operating Officer (COO) and Chief Financial Officer (CFO). Ms. Kim is an experienced finance, corporate development, and operations executive with a strong track record, especially in drug discovery and the induced proximity landscape.
January 9, 2024VantAI Secures Renewed Support from Blueprint Medicines to Chart New Frontiers in Induced Proximity Drug DiscoveryVantAI, a leader in the fields of drug discovery and generative AI, announced today it has entered into an amended and restated collaboration and license agreement with Blueprint Medicines, a leading precision medicine company, to design and advance novel targeted protein degrader therapies to address important areas of medical need.
September 29, 2023VantAI Announces Formation of Scientific Advisory BoardVantAI, a leading company focused on the application of artificial intelligence to drug discovery, today announced its newly formed Scientific Advisory Board (SAB). VantAI’s SAB members are experts in protein design, whole-proteome structural interactomics, and generative AI for small molecule drug design
July 27, 2023Geometric Deep Learning Pioneer Michael Bronstein joins VantAI as Chief Scientist in Residence to Help Drive Artificial Intelligence Breakthroughs in Drug DiscoveryDr. Bronstein, the DeepMind Professor of AI at Oxford, will help VantAI unlock the potential of induced proximity
April 20, 2022VantAI Forms Research Collaboration with Boehringer Ingelheim to Identify Novel Protein DegradersVantAI will pair its induced proximity platform with BI’s deep early discovery experience to identify targeted protein degraders with enhanced properties for traditionally “undruggable” targets
April 13, 2022VantAI Announces Multi-Year Protein Degrader Discovery Collaboration with JanssenVantAI, an AI-first induced-proximity company, today announced it has entered into a multi-year collaboration agreement with Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson
February 28, 2022Blueprint Medicines and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein Degrader TherapiesCollaboration will leverage Proteovant's Artificial Intelligence-enhanced targeted protein degradation platform and Blueprint Medicines' small molecule precision medicine capabilities to address medical needs in oncology and hematology
